But what was most intriguing to me was the blatant and fascinating analogies that this New York Times writer made between the internet space, as they call it, and the biotech area. Now that you are able to work 'URL,' 'click-through' and 'middleware' into your conversation, it's time to start learning a new dialect. The antivirus software in the computer area goes with antibodies. Interface, in the new economics in the computer area, goes with phenotype. I leave that to the scientists to analyze the comparison there.
Hot link goes with genetic marker.
And HTML he analogizes to ATGC, adenine, thymine, guanine, and cytosine, which makes a certain amount of sense in that they both are codes and means of communication. But interesting analogies aside or perhaps farfetched analogies aside, I think this is symptomatic of the fact that we are at a moment where biotech is really poised to take off, both from a business standpoint, from a product standpoint, financially and of course legally in terms of the growth of a legal market in the biotech area, both in terms of inside and outside counsel. And since this is such a rapidly changing market and a growing market, my sense is that a lot of you will probably have a questions to ask of one or more of the panelists, so I am going to leave considerable room for questions from the floor.